Fresenius SE Walks Away from $4.3 Billion Takeover of Akorn

Fresenius SE ended its pending acquisition of Akorn over a probe that found problems with product development and data. Fresenius issued a statement that said it's decision was based on a number of factors including material breaches of FDA data integrity standards.